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OBJECTIVE — Type 2 diabetes is known to be associated with decrements in memory and
executivefunctionsandinformation-processingspeed.Itislessclear,however,atwhichstageof
diabetes these cognitive decrements develop and how they progress over time. In this study, we
investigated cognitive functioning of patients with recent screen-detected type 2 diabetes, thus
providing insight into the nature and severity of cognitive decrements in the early stage of the
disease. Possible risk factors were also addressed.
RESEARCH DESIGN AND METHODS — Included in this study were 183 diabetic
patients from a previously established study cohort and 69 control subjects. A full neuropsy-
chologicalassessment,addressingsixcognitivedomains,wasmadeforeachparticipant.Rawtest
scores were standardized into z scores per domain and compared between the groups. Possible
risk factors for cognitive decrements were examined with multivariate linear regression.
RESULTS — Relative to scores for the control group, mean z scores were between 0.01 and
0.2 lower in the diabetic group across all domains, but after adjustment for differences in IQ
between patients and control subjects, only memory performance was signiﬁcantly reduced
(mean difference –0.15 [95% CI –0.28 to 0.03]). A history of macrovascular disease and
current smoking were signiﬁcant determinants of slower information-processing speed in pa-
tients with diabetes.
CONCLUSIONS — This study shows that modest cognitive decrements are already present
at the early stage of type 2 diabetes. A history of macrovascular disease and smoking are signif-
icant risk factors for some early decrements.
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T
ype 2 diabetes is associated with ac-
celerated cognitive decline (1) and
an increased risk of dementia (2,3),
particularly in older individuals. Previous
studies have shown decrements in mem-
ory function, executive function, and in-
formation-processing speed (4,5). These
decrements in cognitive functioning are
associatedwithmodestbrainatrophyand
vascular lesions on brain magnetic reso-
nance imaging (6). Diabetes-related fac-
tors, such as insulin resistance, chronic
hyperglycemia, hypertension, and lipid
disorders probably are relevant determi-
nants (7,8).
Itisunclearinwhichstageofdiabetes
the cognitive decrements become mani-
fest and how they progress over time.
Most studies have focused on patients
with a known history of diabetes of sev-
eral years (9). However, type 2 diabetes
typicallydevelopsinsidiouslyandmayof-
ten be undiagnosed in the early stages.
Therefore, cognitive decrements may
start to develop years before the actual
diagnosis, even in the pre-diabetes stages.
Detailed neuropsychological data on the
early stage of type 2 diabetes are not yet
available. Moreover, possible risk factors
for early cognitive decrements are not
completely known.
In this study we assessed cognition in
the early stage of diabetes by means of a
detailed neuropsychological assessment
(NPA) in a substantial population of pa-
tients with recent screen-detected diabe-
tes. Possible risk factors were also
addressed.
RESEARCH DESIGN AND
METHODS— The Anglo-Danish-
Dutch Study of Intensive Treatment in
People with Screen Detected Diabetes in
Primary Care (ADDITION) study is a
multinational randomized trial involving
3,057 screen-detected type 2 diabetic pa-
tients that compares the effectiveness of
an intensiﬁed multifactoral treatment
with usual care on 5-year cardiovascular
morbidityandmortalityratesinaprimary
care setting (10). In the Netherlands,
56,987individualswithoutknowndiabe-
tes were offered a questionnaire, and
thosewithascoreabovethresholdunder-
went further glucose testing. Eventually,
586 participants had a diagnosis of type 2
diabetes according to the World Health
Organization 1999 criteria (11), and 498
individuals were included in the study.
Inclusion started in 2002 and ended in
2004.
IntheADDITIONstudy,usualcareis
performed according to the different na-
tional guidelines from the three countries
(in the Netherlands, the guidelines are
from the Dutch College of General Prac-
titioners[12]).Theintensiﬁedmultifacto-
rial treatment consists of lifestyle advice
regarding diet, physical activity, and
smoking; protocol-driven strict regula-
tion of blood glucose (A1C 6.5–7.0%),
blood lipids (cholesterol 3.5 mmol/l),
and blood pressure (130/80 mmHg);
and in those with blood pressure
120/80 mmHg prescription of acetyl-
salicylic acid and an ACE inhibitor. The
primary outcome measure of the study is
the combination of cardiovascular mor-
bidity and mortality, all revasculariza-
tions, or nontraumatic amputations,
whichever came ﬁrst.
Inclusion in the cognition part of the
ADDITION study
Cognition was assessed in an add-on
project to the main ADDITION study in
the Netherlands. Patients were invited to
participate by an information letter from
the study group and their family physi-
cian. Control subjects were peers of the
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for age, sex, and level of education. All
patients and control subjects gave in-
formed consent. Time between initial
screening and inclusion in the Cognition
part of the ADDITION study was 3–4
years.
Inclusion criteria
Inclusion and exclusion criteria for the
present study were identical to those of
the ADDITION study. All participants
were aged 50–70 years at time of screen-
ing (2002–2004). Within 6 weeks after
diagnosis of type 2 diabetes, treatment
started. Randomization was performed at
the practice level, so participants were
treated according to the group (intensi-
ﬁed treatment/usual care) their family
physicianhadbeenrandomlyassignedto.
NPA was performed 3.6  0.56
(mean  SD) years after the screening
date. Patients were excluded from the
ADDITION trial if they were known to
have a history of alcohol or drug abuse,
psychosis, personality disorder, demen-
tia, or emotional, psychological, or neu-
rological disorder, unrelated to diabetes,
thatwaslikelytoinvalidateinformedcon-
sent or limit their ability to comply with
the protocol requirements. For both the
ADDITION trial and the Cognition part,
individuals with a previous noninvalidat-
ingstrokecouldparticipate.Atthetimeof
screening, participants with or treated for
malignant disease or other disease that
limited life expectance to 5 years were
excluded. Control subjects had a fasting
blood glucose 7.0 mmol/l, according to
American Diabetes Association criteria
(13).
NPA
The NPA was performed with a previ-
ouslyestablishedtestbatteryconsistingof
12 verbal and nonverbal tasks addressing
sixcognitivedomains(abstractreasoning,
memory function, information-process-
ing speed, attention and executive func-
tion, and visuoconstruction) as described
previously (14). For the present study,
the domain language comprehension was
added and assessed with the Token Test
(short form) (15). The domain memory
was divided into four subdomains: work-
ing memory, immediate memory and
learningrate,forgettingrate,andinciden-
tal memory (the amount of information
that can be memorized if one was not ex-
plicitly asked to remember something)
(14). IQ was measured by the Dutch ver-
sion of the National Adult Reading Test
(NART) (16). This test is constructed to
estimate premorbid levels of intelligence
and is relatively independent of brain
damage acquired after adulthood (16).
Adepressionscale(CommunityMen-
tal Health Assessment) (17) was used to
assess the potential effect of mood distur-
bances on cognition. Scores 16 were la-
beled as depressive symptoms.
Physicalexaminationandadministra-
tion of the neuropsychological tests were
performed at the patients’ homes. The
tests were administrated in a ﬁxed order,
and the entire battery took about 90 min
to complete.
Participant characteristics and risk
factor assessment
Demographic variables and possible risk
factors were recorded in a standardized
interview.Educationallevelwasrecorded
using seven categories (1, 6 years of ed-
ucation; 2, 6 years; 3, 8 years; 4, 9 years;
5, 10–11 years; 6, 12–18 years; and 7,
18 years of education). Height and
weight were measured, and BMI was cal-
culated as weight in kilograms divided by
the square of height in meters. Smoking
was classiﬁed as current, past, or never.
Alcoholconsumptionwasrecordedusing
sixcategories(0,noalcoholatall;1,upto
3 units/week; 2, 4–10 units/week; 3,
11–20 units/week; 4, 21–30 units/week;
and 5, 30 units/week). Participants in
category 5 were excluded. A1C (percent)
andcholesterollevel(millimolesperliter)
were measured in the week of the NPA
andanalyzedattheregionalhospital.Sys-
tolic and diastolic blood pressures (milli-
meters of mercury) were measured at the
beginning and the end of the neuropsy-
chological assessment; measurements
wereaveraged.Hypertensionwasdeﬁned
as a mean systolic blood pressure 160
mmHg, a mean diastolic blood pressure
95 mmHg, or use of blood pressure–
lowering medication. These relatively
high cutoff values were used because oth-
erwise 90% of the patients would be
classiﬁed as being hypertensive, which
would hamper the assessment of the role
of this risk factor in the regression analy-
ses. Macrovascular disease was deﬁned as
history of myocardial infarction, stroke,
or surgery or endovascular treatment for
carotid, coronary, or peripheral arterial
disease.
Analysis
The differences between patients and
control subjects were examined with Stu-
dent’s t tests for means, Mann-Whitney U
tests for nonparametric data, and 
2 tests
for proportions. To analyze the difference
in cognitive functioning between diabetic
patients and control subjects, raw test
scores for the NPA of both groups were
standardized into z scores per domain.
Mean z scores of the six cognitive do-
mains were compared between the
groups with univariate ANOVAs. Esti-
mated mean differences between group
differences were calculated and are pre-
sented with 95% CIs. Because the esti-
mated premorbid IQ was signiﬁcantly
different between diabetic patients and
control subjects, the NART-IQ was used
asacovariate.Tofurtherassessthepoten-
tial confounding effect of the NART-IQ
imbalance, we performed a secondary
analysis including all the control subjects
(n  69) and an exact age-, sex-, and
NART-IQ–frequency matched selection
of the patients (n  143).
The relation between metabolic and
vascular risk factors and cognition within
the type 2 diabetic patients was assessed
with linear regression analyses (adjusted
for sex, age, and NART-IQ). To limit the
number of analyses, only the domains of
information-processing speed and mem-
ory were entered in these regression anal-
yses,becausethesedomainsareknownto
be particularly sensitive to the effects of
type 2 diabetes (9).
RESULTS
Participant Characteristics
A total of 183 patients with diabetes and
69 control subjects were included in the
Cognition part of the ADDITION study.
Patients and control subjects were bal-
anced on sex, age, and educational level
(Table 1). However, control subjects had
a signiﬁcantly higher estimated premor-
bid IQ.
There were differences in the meta-
bolic and vascular proﬁles between pa-
tients and control subjects (Table 1).
Control subjects had a signiﬁcantly lower
BMI, and they consumed signiﬁcantly
more units of alcohol per week than the
patient group.
Vascular risk factors in patients in
both treatment groups were well con-
trolled. Those who received multifactoral
treatment had a slightly lower A1C level
(mean  SD difference –0.23  0.07%),
cholesterol (mean difference –0.53 
0.14 mmol/l), and mean arterial pressure
(difference –3.05  1.78 mmHg) than
those who received usual care.
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The diabetic group performed signiﬁ-
cantly worse on memory functions, infor-
mation-processing speed, attention, and
executive functions and language com-
prehension in the unadjusted analyses,
but the mean differences between the
groups were small (–0.21 to –0.35) (Ta-
ble 2). After adjustment for NART-IQ,
only memory functions differed signiﬁ-
cantly between the groups (–0.15). The
memory subdomains “immediate mem-
ory and learning rate” and “incidental
memory” differed signiﬁcantly between
thegroupsafteradjustmentforNART-IQ.
The results of the secondary analyses, in a
selectedsubpopulationwithexactmatch-
ingforage,sex,andNART-IQ,showedan
identical cognitive proﬁle with similar ef-
fect sizes (results not shown). There were
no signiﬁcant differences in cognitive
functioning between the patients who re-
ceived multifactor treatment compared
with patients who received usual care (re-
sults not shown).
Possible risk factors
Age was inversely related with perfor-
mance on tasks for memory and informa-
tion-processing speed in diabetic patients
(Table 3). Neither sex nor HbAl levels,
blood pressure, cholesterol levels, or BMI
was signiﬁcantly related to cognitive per-
formance.Ahistoryofmacrovasculardis-
ease, however, was associated with
reduced information-processing speed.
Currentsmokingalsohadasigniﬁcantef-
fect on the reduced information-
processing speed. Depressive symptoms
were not signiﬁcantly related to memory
functions or information-processing
speed. In control subjects, only age was
inversely related with performances on
memory and information-processing
tasks (not shown in table).
CONCLUSIONS — This study shows
that patients with recent screen-detected
type 2 diabetes performed signiﬁcantly
worse on memory functions, in particu-
lar, the immediate and the incidental
memory,comparedwithcontrolsubjects.
A history of macrovascular diseases and
currentsmokingwerethestrongestdeter-
minants of a lower information-
processing speed in the diabetic group.
The effect sizes for the difference in
cognition between the diabetic and con-
trol groups found in this study are small
compared with those in other studies (9),
possibly reﬂecting the relatively short du-
ration of diabetes in our population. In-
deed, in a previous study with the same
NPA battery, we found effect sizes of 0.3–
0.4 among patients with a mean diabetes
duration of 8 years (8). Another study us-
ing the same assessment battery in pa-
tients with a diabetes duration of 5–9
years showed effect sizes of 0.2–0.3 (18).
Diabetesdurationthusseemstobelinked
totheeffectsizesofthestudies:thelonger
the known diabetes duration, the bigger
the effect size. In the present study we
observed a small difference in language
comprehension between patients and
control subjects that was not signiﬁcant
afteradjustmentforNART-IQ.Themean-
ingofthisﬁndingisnotclear.Thedomain
language comprehension is seldom ad-
dressedinstudiesoncognitioninpatients
with type 2 diabetes. Moderate correla-
tionsbetweenthetokentestandmeasures
ofshort-termmemoryhavebeenreported
in a previous study on nondiabetic sub-
jects (19); however, our results do not in-
dicate that our patients performed worse
on measures of short-term memory
(working memory). The observed small
effect on this test is well outside the range
ofwhatwouldbeconsideredasabnormal
performance and is therefore unlikely to
confound performance on the other cog-
nitive tests.
Further research is necessary to see
how the cognitive decrement in our pa-
tients will develop over time and whether
they also will develop problems in execu-
tive functions and information-
processing speed as described in other
studies. The patients included in this
Table 1—Participant characteristics
Patients with
type 2 diabetes
Control
subjects
n 183 69
Sex (% males) 61.2 47.8
Mean age (years) 63.0  5.4 62.7  6.4
Education level (1–7) 4 (4–5) 5 (4–6)
Estimated premorbid IQ 96.7  19.6 103.8  16.3*
BMI (kg/m
2) 30.4  5.3 27.4  4.2*
Current smoking (%) 21.2 11.8
Alcohol (0–5) 1 (0–2) 2 (1–3)†
Depressive symptoms (%) 9.8 5.8
A1C (%) 6.2  0.5 5.5  0.3*
Cholesterol (mmol/l) 4.1  1.0 5.7  1.0*
Ùse lipid-lowering medication (%) 78.7 15.9*
Systolic blood pressure (mmHg) 143  20 140  21
Diastolic blood pressure (mmHg) 82  10 81  12
Hypertension (%) 85.2 36.2*
Use antihypertensive drugs (%) 81.4 23.2*
Macrovascular disease (%) 14.8 43*
Data are means  SD, proportion (in percent), and median (interquartile range) unless indicated otherwise.
*P  0.01; †P  0.05.
Table 2—Estimated mean differences (95% CI)
Unadjusted Adjusted for NART-IQ
Abstract reasoning 0.20 (0.48 to 0.08) 0.01 (0.26 to 0.23)
Memory 0.21 (0.32 to 0.08)† 0.15 (0.28 to 0.03)†
Working memory 0.20 (0.42 to 0.01) 0.07 (0.27 to 0.13)
Immediate memory and
learning rate 0.24 (0.41 to 0.06)* 0.18 (0.35 to 0.003)†
Forgetting rate 0.04 (0.18 to 0.26) 0.04 (0.18 to 0.26)
Incidental memory 0.49 (0.73 to 0.17)* 0.42 (0.71 to 0.14)*
Information processing speed 0.26 (0.48 to 0.03)† 0.13 (0.33 to 0.08)
Attention and executive functions 0.23 (0.42 to 0.04)† 0.12 (0.29 to 0.05)
Visuoconstruction 0.23 (0.52 to 0.05) 0.10 (0.37 to 0.17)
Language comprehension 0.35 (0.65 to 0.04)† 0.19 (0.49 to 0.11)
*P  0.01; †P  0.05.
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second NPA will be performed in a few
years.
The relation between macrovascular
diseases, smoking, and cognition has also
beenfoundinpreviousstudiesofpatients
with diabetes (8,20). Traditionally, hy-
pertension is also thought to mediate the
association between diabetes and cogni-
tivedysfunction(4,21),butresultsofpre-
vious, mostly cross-sectional, studies do
notconsistentlyshowthisrelation,inline
with our ﬁndings. Also in nondiabetic
subjects, the association between hyper-
tension and cognitive functioning varies
withageandtimeofexposureandismost
evident when blood pressure is assessed
in midlife and cognition in late life (22).
Therefore, the association may be less ev-
ident in a cross-sectional study in a rela-
tively older population, such as ours.
Regarding glycemic control, the liter-
aturemostlyshowsanegativerelationbe-
tween A1C (chronic exposure to
hyperglycemia) and cognition in type 1
(23) and type 2 diabetes (24,25). We
could not conﬁrm this relationship. It is
possiblethatwedidnotﬁndthisrelation-
ship because of the relatively strict meta-
bolic control in our patients, but it is also
possiblethatthenegativeeffectofA1Con
cognition becomes more evident after
longer diabetes duration.
A strength of our study is the mea-
surement of cognitive functions in the
earlystageofthedisease.Previousstudies
focused mainly on patients with a longer
diabetes duration. This study gives more
information on early cognitive decre-
ments and shows, in combination with
other studies that used the same NPA in
patients with a longer duration of diabe-
tes, that the decrements seem to be pro-
gressive over time.
A limitation of our study is the differ-
ence in IQ scores of patients and control
subjects. Control subjects had signiﬁ-
cantly higher IQ scores compared with
those for the diabetic patients. We there-
fore had to adjust the analyses for NART-
IQ. In a secondary analysis with exact
matching for age, sex, and NART-IQ, pa-
tients still performed poorer on memory
functions than control subjects. Besides a
difference in IQ scores, there also was a
nonsigniﬁcant higher proportion of men
in the patient group, but sex was unre-
latedtoperformancesinanycognitivedo-
main (Table 3).
Another limitation is the time be-
tween screening and the NPA, which is
between 3 and 4 years. Although this pe-
riodisrelativelyshort,wecannotsayany-
thing about the cognitive functioning in
the ﬁrst stage of type 2 diabetes. On the
other hand, because of the screening pro-
cedure, the diabetic patients in our study
are likely to have had their diabetes diag-
nosed some years earlier; thus, they may
be in the same period of their disease as
patients in usual care with a recent diag-
nosis of type 2 diabetes.
Because of the delay between screen-
ing and the NPA, half of the diabetic pa-
tients had received multifactoral
intensiﬁed treatment for a period of 3–4
years. Although levels of A1C, choles-
terol, and blood pressure were indeed
better in the intensively treated group,
both groups showed good control for
these risk factors, and no effect of treat-
ment allocation on cognition was ob-
servedinthepresentinterimanalysis.Itis
possible that a longer treatment duration
or contrast in risk factor levels between
the groups is required to observe effects
on cognition. This possibility will be ad-
dressed in the follow-up study, once the
treatment period has been completed.
In summary, cognitive decrements
can be found in the early stages of type 2
diabetes. This ﬁnding may have implica-
tions for diabetes education and self-
management behavior in diabetic
patients. Diabetes educators should at
least take into account the immediate
memory and learning rate and the inci-
dental memory of patients with a recent
diagnosisofdiabetes.Ifonewishestopre-
vent diabetes-associated cognitive decre-
ments, interventions may need to be
initiated at a very early stage. Offering a
smoking cessation consultation would be
the best option in those patients who are
smokers. Whether other therapies might
be beneﬁcial to decrease the risk on cog-
nitive impairment remains uncertain.
Acknowledgments— The ADDITION study
in the Netherlands was funded by grants from
Novo Nordisk Netherlands, GlaxoSmithKline
Netherlands, and Merck Netherlands. No
other potential conﬂicts of interest relevant to
this article were reported.
References
1. Cukierman T, Gerstein HC, Williamson
JD. Cognitive decline and dementia in di-
abetes—systematic overview of prospec-
Table 3—Determinants of performance on memory and information processing speed, adjusted for sex, age, and NART-IQ (regression
analyses)
Patients with type 2 diabetes
Memory Information processing speed
B  B 
Age 0.02 (0.04 to 0.01)* 0.26 0.07 (0.08 to 0.05)* 0.44
Sex 0.03 (0.16 to 0.10) 0.03 (0.27 to 0.12) 0.04
BMI 0.003 (0.01 to 0.02) 0.03 0.02 (0.04 to 0.001) 0.11
Current smoking 0.04 (0.20 to 0.12) 0.03 0.26 (0.50 to 0.03)† 0.13
A1C 0.004 (0.13 to 0.14) 0.004 0.004 (0.20 to 0.20) 0.002
Cholesterol 0.02 (0.05 to 0.09) 0.04 0.07 (0.17 to 0.03) 0.08
Hypertension 0.06 (0.13 to 0.24) 0.04 0.17 (0.47 to 0.10) 0.08
Systolic blood pressure (per 10 mmHg) 0.001 (0.03 to 0.04) 0.01 0.02 (0.04 to 0.07) 0.04
Diastolic blood pressure (per 10 mmHg) 0.04 (0.10 to 0.03) 0.08 0.04 (0.13 to 0.05) 0.05
Macrovascular disease 0.13 (0.28 to 0.02) 0.12 0.30 (0.51 to 0.09)* 0.17
Depressive symptoms 0.08 (0.31 to 0.14) 0.05 0.01 (0.34 to 0.35) 0.002
Data are regression coefﬁcient B (95% CI) and standardized .* P  0.01; †P  0.05.
Cognition in early stage of type 2 diabetes
1264 DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009tive observational studies. Diabetologia
2005;48:2460–2469
2. Arvanitakis Z, Wilson RS, Bienias JL,
Evans DA, Bennett DA. Diabetes mellitus
and risk of Alzheimer disease and decline
in cognitive function. Arch Neurol 2004;
61:661–666
3. Ott A, Stolk RP, van Harskamp F, Pols
HAP, Hofman A, Breteler MMB. Diabetes
mellitusandtheriskofdementia.Neurol-
ogy 1999;53:1937–1942
4. StewartR,LiolitsaD.Type2diabetesmel-
litus,cognitiveimpairmentanddementia.
Diabet Med 1999;16:93–112
5. van den Berg E, Kessels RPC, Kappelle LJ,
de Haan EHF, Biessels GJ. Type 2 diabe-
tes, cognitive function and dementia: vas-
cular and metabolic determinants. Drugs
Today 2006;42:741–754
6. Manschot SM, Brands AMA, van der
Grond J, Kessels RPC, Algra A, Kappelle
LJ, Biessels GJ. Brain magnetic resonance
imaging correlates of impaired cognition
in patients with type 2 diabetes. Diabetes
2006;55:1106–1113
7. Biessels GJ, Staekenburg S, Brunner E,
BrayneC,ScheltensP.Riskofdementiain
diabetes mellitus: a systematic review.
Lancet Neurol 2006;5:64–74
8. ManschotSM,BiesselsGJ,deValkH,AlgraA,
Rutten GEHM, van der Grond J, Kappelle LJ.
Metabolic and vascular determinants of im-
paired cognitive performance and abnormali-
ties on brain magnetic resonance imaging in
patients with type 2 diabetes. Diabetologia
2007;50:2388–2397
9. Awad N, Gagnon M, Messier C. The rela-
tionship between impaired glucose toler-
ance, type 2 diabetes, and cognitive
function. J Clin Exp Neuropsychol 2004;
26:1044–1080
10. Sandbaek A, Grifﬁn SJ, Rutten G, Davies
M, Stolk R, Khunti K, Borch-Johnsen K,
Wareham NJ, Lauritzen T. Stepwise
screening for diabetes identiﬁes people
with high but modiﬁable coronary heart
diseaserisk:theADDITIONstudy.Diabe-
tologia 2008;51:1127–1134
11. Alberti KGMM, Zimmet PZ. Deﬁnition,
diagnosis and classiﬁcation of diabetes
mellitus and its complications. Part 1: di-
agnosis and classiﬁcation of diabetes mel-
litus. Provisional report of a WHO
consultation. Diabet Med 1998;15:539–
553
12. Rutten GEHM, De Grauw WJC, Nijpels
G, Goudswaard AN, Uitdewaal PJM, Van
derDoesFEE,HeineRJ,VanBallegooieE,
Verduijn MM, Bouma M. NHG-standard
diabetes mellitus type 2. Huisarts Weten-
schap 2006;49:137–152
13. American Diabetes Association. Stan-
dards of medical care for patients with
diabetes mellitus. Diabetes Care 25:213–
229
14. Brands AMA, Kessels RPC, Hoogma
RPLM, Henselmans JML, van der Beek
Boter JW, Kappelle LJ, de Haan EHF,
Biessels GJ. Cognitive performance, psy-
chologicalwell-being,andbrainmagnetic
resonance imaging in older patients with
type 1 diabetes. Diabetes 2006;55:1800–
1806
15. Graetz P, de Bleser R, Willmes K. Akense
Afasie Test. Lisse, the Netherlands, Swets
& Zeitlinger, 1992
16. Schmand B, Lindeboom J, van Harskamp
F. Nederlandse Leestest voor Volwassenen
[Dutch Adult Reading Test]. Lisse, the
Netherlands, Swets & Zeitlinger, 1992
17. Bouma J, Ranchor AV, Sanderman R, van
Sonderen E. Het meten van symptomen van
depressie met de CES-D: een handleiding.
Groningen, the Netherlands, Noordelijk
Centrum voor Gezondheidsvraagstuk-
ken, 1995
18. van den Berg E, Dekker J, Nijpels G, Kes-
sels RPC, Kappelle LJ, de Haan EHF,
Heine RJ, Stehouwer CDA, Biessels GJ.
Cognitive functioning in elderly persons
with type 2 diabetes and metabolic syn-
drome: the Hoorn study. Dement Geriatr
Cogn Disord 2008;26:261–269
19. Lesser R. Verbal and non-verbal memory
components in the Token Test. Neuro-
psychologia 1976;14:79–85
20. Arvanitakis Z, Wilson RS, Li Y, Aggerwal
NT,BennettDA.Diabetesandfunctionin
different cognitive systems in older indi-
viduals without dementia. Diabetes Care
2006;29:560–565
21. HassingLB,HoferSM,NilssonSE,BergS,
Pedersen NL, McClearn G, Johansson B.
Comorbid type 2 diabetes mellitus and
hypertension exacerbates cognitive de-
cline: evidence from a longitudinal study.
Age Ageing 2004;33:355–361
22. Kloppenborg RP, van den Berg E, Kap-
pelle LJ, Biessels GJ. Diabetes and other
vascular factors for dementia: which fac-
tor matters most? A systematic review.
Eur J Pharmacol 2008;585:97–108
23. Brands AMA, Biessels GJ, de Haan EHF,
Kappelle LJ, Kessels RPC. The effects of
type1diabetesoncognitiveperformance.
Diabetes Care 2005;29:726–735
24. van Harten B, Oosterman J, Muslimovic
D,vanLoonBJP,ScheltensP,Weinstein
HC. Cognitive impairment and MRI
correlates in the elderly patients with
type 2 diabetes. Age Ageing 2007;36:
164–170
25. Munshi M, Grande L, Hayes M, Ayres D,
Suhl E, Capelson R, Lin S, Milberg W,
WeingerK.Cognitivedysfunctionisasso-
ciated with poor diabetes control in older
adults. Diabetes Care 2006;29:1794–
1799
Ruis and Associates
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1265